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Purpose: Calcitriol, or 1,25-hydroxycholecalciferol, is the active form of vitamin D. It 
binds and activates vitamin D receptor (VDR). Infertility and defective folliculogenesis 
have been observed in female vdr-knockout mice; however, whether VDR polymor-
phisms affect human ovarian responses to controlled ovarian stimulation (COS) remains 
unclear. We hypothesized that VDR polymorphisms are associated with infertility and 
COS responses. Thus, we evaluated the association between the TaqI, BsmI, and FokI 
VDR polymorphisms and ovarian responses in women undergoing COS.
Methods: In this study, we recruited a control group (n = 121) comprising volunteers 
with a history of natural conception and a second group of women undergoing COS 
(n =  70). TaqI, BsmI, and FokI genotyping was performed via restriction fragment 
length polymorphism analysis or TaqMan qPCR and Sanger sequencing. Intrafollicular 
25(OH)D contents were measured in follicular fluid collected from COS patients during 
oocyte retrieval. Ovarian response parameters were obtained from patient medical 
records.
results: There were no significant differences in the genotype frequencies of VDR 
polymorphisms (TaqI, BsmI and FokI) between the control and COS groups. However, 
the allele frequency of TaqI (C allele) was significantly lower in the COS group than in the 
control group (p = 0.02). Follicle number but not oocyte number was lower in patients 
with TaqI polymorphic (TC/CC) genotypes (p =  0.03). Importantly, the ratio between 
Abbreviations: BMI, body mass index; COS, controlled ovarian stimulation; FF, follicular fluid; E2, estrogen; P4, proges-
terone; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; hCG, human chorionic gonadotropin; 
1,25(OH)2D, 1,25-Hydroxycholecalciferol; 25(OH)D, 25-Hydroxyvitamin D; 25(OH)D3, 25-Hydroxycholecalciferol; 25(OH)
D2, 25-Hydroxyergocalciferol; HWE, Hardy–Weinberg equilibrium; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm 
injection; LH, luteinizing hormone; OR, odds ratio; RFLP, restriction fragment length polymorphism; SNP(s), single-nucleotide 
polymorphism (s); VDR, vitamin D receptor.
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the number of follicles retrieved and intrafollicular estradiol concentrations was higher in 
patients with the TC/CC TaqI genotypes (p < 0.02).
conclusion: We identified an association between the VDR TaqI polymorphism and 
reduced follicle number in women undergoing COS, suggesting that VDR signaling 
affects the ovarian response to stimulation via unknown mechanisms.
Keywords: calcitriol, VDR polymorphisms, 25(Oh)D, TaqI, folliculogenesis, infertility
conditions such as osteoporosis (28), colorectal cancer (29), and 
metabolic syndrome (30). In the context of reproductive medi-
cine, VDR polymorphisms have been associated with polycystic 
ovarian syndrome and endometriosis (17, 31–38), although 
these results are inconclusive and require further investigation.
25(OH)D deficiency is now recognized as a pandemic condi-
tion (39). In Brazil, 25(OH)D deficiency is largely detected in 
women of different ages, including elderly and postmenopausal 
women (40) and women of reproductive age (41). Controlled 
ovarian stimulation (COS), which aims to increase the success 
rate of in vitro fertilization (IVF) through stimulation of follicu-
logenesis, revealed a decrease in the pregnancy (42) and fertiliza-
tion rates (43) in women with lower 25(OH)D concentrations.
Moreover, other studies have demonstrated that women 
with replete serum concentrations of 25(OH)D (42) or at 
least sufficient 25(OH)D in the follicular fluid (FF) had lower 
pregnancy and fertilization rates (44). A recent study from our 
group demonstrated that women with lower follicular 25(OH)
D concentrations exhibited better outcomes when treated with 
the COS protocol in that they produced more larger follicles and 
had higher serum estradiol concentrations (45). Despite these 
controversial data, in  vitro and animal model studies strongly 
support a significant role of calcitriol in orchestrating reproduc-
tive processes and IVF outcomes (46). However, further studies 
are warranted to demonstrate a causal relationship between 
25(OH)D status and infertility.
In the present study, we hypothesized that VDR polymor-
phisms are associated with infertility and response to COS. The 
identification of specific VDR polymorphisms that can be shown 
to be related to infertility and response to COS may help clarify the 
causes underlying female infertility and poor ovarian response.
MaTerials anD MeThODs
Patients
Two groups of patients were enrolled for each polymorphism 
analysis. The control group comprised volunteer women with no 
history of reproductive disorders. To be included in the control 
group, volunteers had to declare that they had become pregnant 
through natural conception at least once and had never experi-
enced any difficulties in conceiving. The COS group consisted of 
women who underwent COS for intracytoplasmic sperm injec-
tion (ICSI) at the Fertipraxis Center for Human Reproduction, 
a clinic certified by the Brazilian Health Surveillance Authority 
(ANVISA) and the Latin American Network of Assisted 
Reproduction (REDLARA). We enrolled 62 controls and 47 
inTrODUcTiOn
Calcitriol, or 1,25-hydroxycholecalciferol (1,25(OH)2D), is the 
active form of vitamin D, a steroid hormone that exerts classi-
cal functions in calcium and phosphorus homeostasis and bone 
mineralization (1). Calcitriol binds its nuclear receptor, vitamin 
D receptor (VDR) (2), and has an array of actions in the immu-
nological, cardiovascular (3), and reproductive systems of both 
genders (4). In particular, a number of studies have demonstrated 
an association between 25-hydroxyvitamin D (25(OH)D) con-
centrations and different causes of infertility in animals (3, 5–8) 
and humans (9–14).
VDR expression has been reported in different central 
(hypothalamus and hypophysis) and peripheral reproduc-
tive organs (ovary, uterus, placenta, and oviduct) (13, 15, 16). 
Evidence linking calcitriol and reproductive function has been 
demonstrated in 7-week-old female vdr-knockout mice. These 
animals exhibited uterine hypoplasia, defective folliculogenesis 
(the absence of mature follicles), and associated infertility (6, 
7). Moreover, female vdr-knockout mice exhibited decreased 
aromatase expression and activity in the ovary, and these effects 
were associated with elevated serum luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH) concentrations, indicat-
ing a peripheral rather than a central defect (8) and suggesting a 
role for calcitriol in regulating folliculogenesis.
Genetic alterations in the VDR gene may lead to important 
defects in gene activation. Alterations were reported to affect 
calcium metabolism, cell proliferation, and immune function 
(17). Furthermore, some VDR single-nucleotide polymorphisms 
(SNPs) may contribute to a genetic predisposition to certain 
diseases. SNPs present in the VDR gene alter receptor length 
and decrease its activation in target cells (18). Among these 
polymorphisms, the best described are TaqI, BsmI, and FokI. TaqI 
(rs731236, changes T/C, exon 9) and BsmI (rs1544410, changes 
G/A, intron 8) are present in the 3′ untranslated region (3′ UTR) 
of the VDR gene and are related to modulation of gene and protein 
expression of the receptor. The FokI polymorphism (rs2228570, 
changes T/C, exon 9), in turn, is present in a translated region 
and effects functional activity by generating a longer VDR protein 
with reduced transcriptional activity (19).
These polymorphisms have been previously associated with 
increased risk of developing diabetes (20), tuberculosis (FokI 
polymorphism) (21), specific cancers (22, 23), and multiple scle-
rosis (24). Conversely, they were also associated with protection 
against breast cancer (TaqI polymorphism) (25), osteoporosis 
(26), and asthma (FokI polymorphism) (27). However, no asso-
ciations between VDR polymorphisms have been reported in 
TaBle 1 | Sequences of primers used to amplify each polymorphism and their respective fragments with or without endonucleases.
Polymorphism sense antisense length reference
TaqI (rs731236) CAGAGCATGGACAGGGAGCAA GCAACTCCTCATGGCTGAGGTCTC 495 bp uncut (48)
290, 245 bp cleaved
FokI (rs2228570) AGCTGGCCCTGGCACTGACTCTGCTCT ATGGAAACACCTTGCTTCTTCTCCCTC 265 bp uncut
196, 69 bp cleaved
Pb, pair of bases.
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COS-treated women in the TaqI polymorphism analysis, 57 
controls and 49 COS-treated women in the FokI analysis, and 86 
controls and 54 patients in the BsmI analysis.
This study was approved by the local Ethics Committee and was 
registered on the Brazilian platform of research under the num-
ber 02213812.4.0000.5275. All the enrolled subjects (volunteers 
and patients) provided written informed consent before joining 
the study. In the COS group, clinical data, including hormone 
concentrations [serum and follicular estrogen (E2), progesterone 
(P4), LH, and FSH] and indicators of ovarian response (number 
of follicles and oocytes retrieved), were obtained from patient 
medical records. Clinical data for the control group were obtained 
during patient enrollment and interviews. All patients underwent 
blood collection for further VDR polymorphism genotyping.
cOs Protocol
Controlled ovarian stimulation protocols were performed accord-
ing to the specific clinical requirements of the patients. Briefly, the 
gonadotropin-releasing hormone antagonist analog cetrorelix 
acetate (Cetrotide® 0.25 mg, Merck-Serono, Italy) was adminis-
tered to induce hypophysis suppression, and on the second day 
of menstruation, ovarian stimulation was initiated with synthetic 
FSH alone (Gonal-F®, Merck-Serono, Italy; or Bravelle®, Ferring 
Pharmaceutical, Germany) or FSH and LH (Pergoveris®, Merck-
Serono, Italy; or Menopur®, Ferring Pharmaceutical, Germany) 
treatments. FSH dosage varied from 150 to 300 IU/day, and LH 
dosage ranged from 75 to 300 IU/day.
When at least one follicle had reached 18 mm or at least two 
follicles had reached 16  mm (assessed by ultrasound), human 
chorionic gonadotropin (hCG) (Ovidrel® 250 μg, Merck-Serono, 
Italy) was administered to mimic LH. Thirty-five hours post-
Ovidrel® administration, the oocytes were retrieved, and FF was 
obtained during the follicular aspiration procedure. In addition, 
blood samples were collected for VDR genotyping following FF 
isolation.
Dna extraction
Blood (1 ml) was submitted for genomic DNA extraction from 
peripheral leukocytes via the salting-out technique (47) using a 
commercial Wizard® Genomic DNA purification kit according to 
the manufacturer’s instructions (A1120, Promega, Madison, WI, 
USA). After the extraction, DNA quantity and quality were exam-
ined using a NanoPhotometer (Implen, Munchen, Germany).
genotyping
The genotyping of TaqI (rs731236) and FokI (rs2228570) 
polymorphisms was performed using the restriction fragment 
length polymorphism (RFLP) technique. Table  1 shows the 
primer sequences used for the VDR polymorphism analysis, 
which were validated through the Primer Blast program to 
ensure PCR quality; intron-spanning primers were used to 
avoid contamination with external genomic DNA. To perform 
the PCR reactions, a commercial kit (GoTaq, Promega, USA) 
was used and the conditions were as follows: 95°C for 4 min, 35 
cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 1 min, and 72°C 
for 7 min. DNA samples were digested by TaqI and BseGI (Btscl 
isoschizomers that recognize the same sequence recognized by 
the FokI) endonucleases (Thermo Scientific, EUA). The mix-
tures were incubated at 65°C and 55°C, respectively, to promote 
cleavage. The samples were then subjected to electrophoresis on 
2–4% agarose gels to determine the lengths of the fragments 
and genotyping results (Figures S1 and S2 in Supplementary 
Material).
BsmI (rs1544410) polymorphism genotyping was performed 
using TaqMan Genotyping Master Mix (Applied Biosystems, Foster 
City, CA, USA, 4371355) and a TaqMan® SNP Genotyping Assay 
(Applied Biosystems, PN4351379) in a ViiA™ 7 Real-Time PCR 
System (Applied Biosystems, Foster City, CA, USA). Allele discrimi-
nation was analyzed using the ViiA™ 7 software, and genotyping 
was performed with Genotyping version 3.1 from Thermo Fisher 
Cloud. Furthermore, Sanger sequencing (Big Dye® Terminator v 3.1 
Cycle Sequencing Kit) was performed on the four amplified products 
for which real-time PCR did not achieve accurate results to confirm 
the genotyping assay results (Figure S3 in Supplementary Material). 
The same primers used for amplification were used for genotyping 
assessment (5′CAACCAAGACTACAAGTACCGCGTCAGTG3′ 
and 3′AACCAGCGGGAAGAGGTCAAGGG5′) with 1 cycle at 
96°C for 1 min, 25 cycles at 96°C for 15 s, 50°C for 15 s, and 60°C 
for 4 min. Products of the sequencing reactions were assessed in a 
Genetic Analyzer ABI3500. Sequence analysis was performed using 
MacVector, version 14.
FF collection for 25(Oh)D Measurement
Follicular fluid collection was performed during oocyte capture, 
as previously described (45, 49). Briefly, follicle aspiration was 
undertaken with a transvaginal ultrasound probe as a guide 
(Medison X8®) and a 17G oocyte aspiration needle (Wallace®) 
connected to a closed vacuum system under 90 mmHg of nega-
tive pressure, which was used to empty the follicles. The follicle 
exhibiting the largest diameter, greater than 16 mm, was selected, 
captured and placed in a sterile container. FF was extracted after 
oocyte detection and subsequently frozen in liquid nitrogen. This 
technique allowed the collection of fluid from a single follicle and 
decreased the chance of blood contamination.
TaBle 4 | Allele frequencies of VDR polymorphisms.
Polymorphism allele frequencies (%) Or (95% ci) χ2 (p)
control (n) cOs (n)
TaqI (rs731236) n = 124 n = 94
T 74.0 (92) 60.0 (56) 1.95 (1.097–3.5) 5.24 (0.02)*
C 26.0 (32) 40.0 (38)
FokI (rs2228570) n = 114 n = 98
T 69.0 (79) 64.0 (63) 1.25 (0.71–2.21) 0.60 (0.44)
C 31.0 (35) 36.0 (35)
BsmI (rs1544410) n = 172 n = 108
G 59.3 (102) 50.0 (54) 1.45 (0.90–2.35) 2.32 (0.12)
A 40.7 (70) 50.0 (54)
COS, controlled ovarian stimulation. OR, odds ratio. IC, confidence interval. χ2, chi-
squared test (values above 3.84; p < 0.05).
*Significant p value.
TaBle 3 | Genotype frequencies of VDR polymorphisms.
Polymorphism genotype frequencies (%) χ2 (p)
control (n) cOs (n)
TaqI (rs731236) n = 62 n = 47
TT 62.9 (39) 42.6 (20) 4.47 (0.10)
TC 22.6 (14) 34.0 (16)
CC 14.5 (9) 23.4 (11)
p (HWE) <0.01 0.13
FokI (rs2228570) n = 57 n = 49
TT 50.9 (29) 47.0 (23) 0.76 (0.68)
TC 36.8 (21) 35.0 (17)
CC 12.3 (7) 18.0 (9)
p (HWE) 0.60 0.23
BsmI (rs1544410) n = 86 n = 54
GG 54.7 (47) 42.6 (23) 2.22 (0.33)
GA 9.30 (8) 14.8 (8)
AA 36.0 (31) 42.6 (23)
p (HWE) <0.01 <0.01
COS, controlled ovarian stimulation; HWE, Hardy–Weinberg equilibrium (p value < 0.05 
is not considered in HWE; p value > 0.05 is considered in HWE). χ2—chi-squared test 
(values above 3.84; p < 0.05).
TaBle 2 | Demographic parameters of control and COS groups.
control cOs p-Value
Age (years) 44 ± 0.9 35 ± 0.5 <0.0001
Height (cm) 161 ± 0.7 164 ± 0.7 <0.01
Weight (kg) 66 ± 1.0 61 ± 1.2 <0.002
BMI (kg/m2) 25.5 ± 4.1 22.5 ± 3.9 <0.0001
BMI, body mass index; COS, controlled ovarian stimulation.
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Quantification of 25(Oh)D
FF 25(OH)D concentrations were assessed using an electro-
chemiluminescence fixation assay (ElecsysTotal Vitamin D total 
assay, Roche Diagnostics, Brazil). The range of measurements 
was 3–70 ng/ml. Inter- and intra-assay variations were 5.9 and 
5.2%, respectively. This technique is based on competition, and 
a vitamin D-binding protein binds 25-hydroxycholecalciferol 
(25(OH)D3) and 25-hyroxyergocalciferol (25(OH)D2).
statistical analysis
Genotype and allele frequencies were calculated based on 
the observed genotypes. Departure from Hardy–Weinberg 
equilibrium (HWE) in the distribution of the genotypes was 
estimated with the χ2 test. If the χ2 test resulted in a p value 
greater than 0.05, the population was considered to be in HWE. 
The influence of each VDR polymorphism on COS variation 
was assessed by an odds ratio (OR) analysis. We performed 
χ2 tests to analyze heterogeneity, and a value of p <  0.05 was 
considered to indicate statistical significance. The dominant 
model, in which heterozygous and homozygous minor alleles 
were grouped, was analyzed.
The Mann–Whitney test was used to investigate possible 
associations between polymorphisms and ovarian response 
variables and to test associations between polymorphisms and 
FF concentrations of 25(OH)D. A p value <0.05 was considered 
statistically significant. All comparisons were performed using 
SPSS (version 22) software. Graphics were generated using Prism 
(version 6) software.
resUlTs
clinical Data
To determine whether the presence of polymorphisms in the 
VDR gene affected the ovarian response of women undergoing 
COS, we extracted clinical data from control volunteers who had 
declared a history of natural conception and from women who 
underwent the COS protocol and ICSI treatment. The demo-
graphic parameters of the control and COS groups are depicted 
in Table 2.
The COS infertility diagnoses in our group were as follows: 
unexplained (37%), tubal factors (18%), ovarian failure (13%), 
endometriosis (13%), female anatomical causes (6%), and other 
causes of infertility (13%), including hypogonadism, colonic 
surgery, ovarian failure and tubal factors, female endocrine fac-
tors, breast cancer, tubal factors and endometriosis, or polycystic 
ovarian syndrome and endometriosis.
analysis of TaqI, BsmI, and FokI VDR 
Polymorphisms
Table  3 shows the genotype frequencies of the VDR polymor-
phisms studied in the control versus COS groups. No differences 
were found, and the FokI polymorphism was in HWE (control: 
p =  0.6, COS: p =  0.23). Table  4 shows the allele frequencies 
of the VDR polymorphisms studied in the control versus COS 
groups. No differences were observed in the BsmI and FokI allele 
frequencies between the control and COS groups. However, the 
TaqI polymorphism exhibited a higher frequency of the C allele 
and a lower frequency of the T allele in the COS group [p = 0.02; 
OR: 1.95 (1.097–3.5)]. We then applied the dominant model and 
identified a considerable trend in the genotype distribution for 
the TaqI polymorphism [p = 0.056, OR: 2.106 (0.979–4.53)].
TaqI Polymorphism and cOs-related 
Variables/25(Oh)D associations
Because an association was detected between infertility and the 
frequency of TaqI alleles, we next examined whether the TaqI 
FigUre 1 | Follicles (a) and retrieved oocytes (B). White bars represent 
women carrying the TT genotype, whereas gray bars represent women 
carrying the TC/CC genotypes. Unpaired t-test. The data are presented as 
the mean ± min and max.
TaBle 6 | Intrafollicular 25(OH)D, E2 and P4 concentrations according to TaqI 
genotype.
TT TT/cc p
Intrafollicular (capitation day) 25(OH)D 22.5 ± 3.1 25.6 ± 2.4 0.4
E2 (ng/ml) 423 ± 91 488 ± 75 0.58
P4 (pg/ml) 18.34 ± 2.7 23.87 ± 41.3 0.69
E2, estradiol; P4, progesterone; 25(OH)D, 25-hydroxycholecalciferol.
The data are expressed as the medians ± SEM.
TaBle 5 | Ovarian stimulation-related variables according to TaqI genotype.
TT Tc/cc p
Day 1 of COS Antral follicles 13.1 ± 1.03 10.9 ± 0.74 0.08
FSH (mU/ml) 6.5 ± 0.74 5.9 ± 0.56 0.54
LH (mU/ml) 4.9 ± 0.59 6.5 ± 0.59 0.08
E2 (pg/ml) 53.5 ± 7.2 83.1 ± 10.8 0.11
P4 (pg/ml) 361 ± 43 340 ± 32.4 0.69
COS duration (days) 9.5 ± 0.45 10.0 ± 0.34 0.39
FSH (UI) 1835 ± 152 1941 ± 168 0.64
COS, controlled ovarian stimulation; E2, estradiol; P4, progesterone; FSH, Follicle-
stimulating hormone; LH, Luteinizing hormone.
The data are expressed as the medians ± SEM.
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polymorphism is associated with variables related to the COS 
protocol. We, therefore, sorted the COS group according to 
genotype based on the dominant model (Table 5). A comparison 
of the TaqI genotypes did not reveal any differences in LH, FSH, 
E2, or P4 concentrations on day 1 of the COS protocol. However, 
there was a trend for women possessing the TC/CC genotypes to 
have a lower number of antral follicles than were found in women 
with the TT genotype (p = 0.08). The duration of COS and the 
FSH dose administered did not differ according to the TaqI 
genotype (Table  5). Similarly, a comparison of TaqI genotypes 
at baseline (Table  6) before COS revealed that there were no 
differences in 25(OH)D, E2, and P4 concentrations on the day 
of oocyte retrieval.
We further analyzed the number of follicles and retrieved 
oocytes according to the TaqI genotypes (Figure  1). A lower 
number of mature follicles was found in women with the TC/CC 
genotypes than in women possessing the TT genotype (p = 0.03). 
However, we found no significant differences in the number of 
oocytes retrieved. We also analyzed the serum concentrations of 
E2 and P4 on the day of hCG administration as well as the ratio of 
intrafollicular E2 to follicles retrieved according to TaqI genotype 
(Figure 2). There were no significant associations between TaqI 
genotypes and serum concentrations of E2 or P4 on the day of 
hCG administration (Figure 2). However, the ratio of intrafol-
licular E2 to retrieved follicles was higher in women with TC/
CC genotypes than in women with the TT genotype (p < 0.02) 
(Figure 2). Our analysis of comorbidities between the two groups 
(TT and TC/CC genotypes) revealed no differences. There were 
no smokers in either group. Hypertension and diabetes were 
not found in any of these patients. The only comorbidity found 
was thyroid dysfunction. In all, 10% of the women with the TT 
genotype and 14% of the women with the TT/CC genotypes had 
thyroid dysfunction.
DiscUssiOn
This work provides the first demonstration of an association 
between the VDR TaqI polymorphic C allele frequency and 
decreased follicle production by women exhibiting different 
causes of infertility. There were no significant differences in 
the genotype and allele frequencies of the FokI and BsmI poly-
morphisms between the COS and control groups. Instead, the 
higher frequencies observed in the group with polymorphic TaqI 
alleles in the COS group indicates that this VDR polymorphism 
is a potentially important SNP candidate that may be involved in 
female fertility.
There is some disagreement in the literature regarding 
the relationship between VDR polymorphisms and infertility 
disorders. Several studies have found that there is a negative 
association between the presence of TaqI, FokI, and BsmI VDR 
polymorphisms and the risk of developing reproductive disor-
ders, such as polycystic ovarian syndrome and endometriosis 
(31–35). Conversely, other studies have found positive associa-
tions (36–38, 50) or no association at all (17) for these variables, 
suggesting that there is a need for further studies to clarify this 
important question.
We did not find an association between follicular 25(OH)
D concentrations and any specific TaqI polymorphism allele 
(C or T), suggesting that these polymorphisms do not alter FF 
25(OH)D concentrations. Importantly, while serum concentra-
tion of 25(OH)D were not evaluated in this study, recent findings 
reported by our (49) and other groups (13, 14, 43, 44, 51) have 
demonstrated that FF accurately reflects plasma 25(OH)D con-
centrations (14, 44) in both fertile and infertile patients.
The above results indicate a lack of a direct relationship between 
FF concentrations of 25(OH)D and infertility and suggest that the 
TaqI polymorphism does have a role in this context. In contrast, 
some studies have demonstrated an association between the TaqI 
C allele and decreased serum 25(OH)D concentrations in women 
with colorectal cancer (52), whereas another study performed 
in a healthy cohort in India (53) demonstrated that the TaqI C 
allele was directly associated with higher serum concentrations 
of 25(OH)D.
FigUre 2 | Serum concentrations of progesterone (a) and estradiol (B) on the day of human chorionic gonadotropin administration and the ratio of serum 
estradiol/to retrieved follicles (c). White bars represent women carrying the TT genotype, whereas the gray bars represent women carrying the TC/CC genotypes. 
Unpaired t-test. The data are presented as the mean ± min and max.
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However, a study of polycystic ovarian syndrome in 
Caucasian women (32) found no association between TaqI 
polymorphic genotypes (TT, TC, CC) and 25(OH)D deficiency. 
This finding is in line with our results, given that we did not 
found any associations between TaqI polymorphism genotypes 
and intrafollicular 25(OH)D concentrations. Altogether, these 
data highlight the relevance of the TaqI polymorphism under 
different conditions and suggest the need for further studies 
investigating the relationship between VDR polymorphisms 
and 25(OH)D serum concentrations in different pathologies, 
including infertility disorders.
Our study has some limitations, including the relatively 
low number of included patients and the fact that we did not 
genotype all three VDR polymorphisms in all samples we 
evaluated. We also observed that there was a lack of HWE in the 
control population due to the exclusion criteria. This decreased 
the size of the study population and may have contributed to 
the observed imbalance in genotype and allele frequencies, 
resulting in a lack of HWE in the study populations. However, 
the COS population was under HWE and exhibited an associa-
tion between the TaqI TC/CC polymorphic genotypes and the 
production of fewer ovarian follicles. These results suggest a 
possible role of the C allele in determining the number of pre-
ovulatory follicles.
The above observation is supported by our data showing a 
higher ratio of retrieved follicles to intrafollicular E2 in women 
with TC/CC genotypes than in women carrying the TT genotype, 
i.e., women who have the TC/TT genotypes exhibited lower E2 
availability in pre-ovulatory follicles. This finding demonstrates 
an important impact of the TaqI polymorphism on follicular 
development and hormone secretory function.
Recent studies have shown that 25(OH)D is present in FF (15, 
19). While there is some controversy regarding the importance of 
FF 25(OH)D concentrations in positive IVF outcomes [for exam-
ple, in patients with chemical pregnancies, embryonic implanta-
tion problems, chemical pregnancy (β-hCG level higher than 
25 mIU/ml), in fertilization rates and in the numbers of embryos 
transferred and oocytes retrieved] (13, 14, 44), VDR mRNA 
and 1-α hydroxylase enzyme are expressed in the ovary (i.e., in 
ovarian cells and granulosa cell cultures) (12, 38), indicating that 
calcitriol activity affects local synthesis and autocrine and/or 
paracrine actions in the ovaries.
In conclusion, this study revealed an association between 
the presence of the C VDR TaqI polymorphism allele and 
infertility. This association is likely mediated by impaired 
calcitriol signaling, which may impact the number of follicles 
in women undergoing COS via mechanisms that are yet to be 
described.
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FigUre s1 | Agarose gel electrophoresis of DNA against a 100 bp DNA ladder 
(Promega) following PCR amplification and restriction fragment length 
polymorphism with the TaqI restriction enzyme. (a) Lane 1, uncut band with a 
length of 495 bp. Lanes 2, 3, 5, and 6 contain uncut 495 bp fragments, 
indicating that these samples have the TT (homozygous) genotype. Lane 4 
contains two bands at 290 and 205 bp, indicating the CC (homozygous) 
genotype. (B) Lanes 1, 3, 4, 5, and 6 contain 495, 290, and 205 bp fragments, 
indicating the TC (heterozygous) genotype. Lane 2 contains an uncut band with 
a length of 495 bp. Lane 7 contains two bands at 290 and 205 bp, indicating the 
CC (homozygous) genotype.
FigUre s2 | Agarose gel electrophoresis of DNA against a 100-bp DNA 
ladder (Promega) following PCR amplification and restriction fragment length 
polymorphism with the BseGI restriction enzyme. (a) Lane 1 contains an 
uncut band at 265 bp. Lane 2 contains fragments at 265 bp, indicating the TT 
(homozygous) genotype. Lane 3 contains two bands at 196 and 69 bp, 
indicating the CC (homozygous) genotype. (B) Lane 1 contains an uncut band 
with a length of 265 bp. Lanes 2 and 3 contains fragments at 265 bp, 
indicating an uncut fragment and, therefore, the TT (homozygous) genotype.
FigUre s3 | DNA fragment sequences in affected and unaffected individuals. 
The BamH1 restriction site sequence is underlined, and the arrows indicate the 
polymorphic site. (a) DNA sequence electropherogram of the wild-type G/G 
genotype (arrow). (B) DNA sequence electropherogram of the homozygous A/A 
polymorphism (arrow). (c) DNA sequence electropherogram of the heterozygous 
G/A polymorphism (arrow).
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